TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Drug Watch
Keywords: Healthcare rationing, QALY, NICE, IQWiG, .
This article has 0 comments
Healthcare rationing: the moral dilemma
If Europe is to ensure that the latest therapies can be made available to all cancer patients who might benefit, getting maximum value from every euro spent on health will be essential. But who is to adjudicate that one patient can’t have something they need, because another with different needs could derive greater benefit for the same money?
» Anna Wagstaff
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.






